Novel Combination Advances in CLL

CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.

The rate of undetectable minimal residual disease at 10-4 in bone marrow was 77%, including a 71% rate among 14 patients with chronic lymphocytic leukemia refractory to prior Bruton tyrosine kinase inhibitors treated with venetoclax, umbralisib, and ublituximab.